Reviewing Spero Therapeutics Inc. (SPRO)’s and Zealand Pharma A/S (NASDAQ:ZEAL)’s results

Both Spero Therapeutics Inc. (NASDAQ:SPRO) and Zealand Pharma A/S (NASDAQ:ZEAL) are Biotechnology companies, competing one another. We will compare their institutional ownership, profitability, risk, dividends, analyst recommendations, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Spero Therapeutics Inc. 11 -0.15 12.36M -2.18 0.00
Zealand Pharma A/S 30 0.00 26.77M 3.00 7.54

We can see in table 1 the earnings per share, gross revenue and valuation of Spero Therapeutics Inc. and Zealand Pharma A/S.


Table 2 represents Spero Therapeutics Inc. (NASDAQ:SPRO) and Zealand Pharma A/S (NASDAQ:ZEAL)’s return on equity, net margins and return on assets.

Net Margins Return on Equity Return on Assets
Spero Therapeutics Inc. 114,338,575.39% -34.5% -31.2%
Zealand Pharma A/S 88,789,386.40% 0% 0%

Analyst Ratings

The Recommendations and Ratings for Spero Therapeutics Inc. and Zealand Pharma A/S are featured in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Spero Therapeutics Inc. 0 0 1 3.00
Zealand Pharma A/S 0 0 2 3.00

Spero Therapeutics Inc.’s upside potential currently stands at 207.83% and an $35 consensus price target. On the other hand, Zealand Pharma A/S’s potential upside is 11.35% and its consensus price target is $36.5. Based on the results given earlier, Spero Therapeutics Inc. is looking more favorable than Zealand Pharma A/S, analysts opinion.

Insider & Institutional Ownership

Institutional investors held 53.1% of Spero Therapeutics Inc. shares and 9% of Zealand Pharma A/S shares. 23.71% are Spero Therapeutics Inc.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Spero Therapeutics Inc. -0.95% -11.87% -4.77% 9.14% -5.63% 68.94%
Zealand Pharma A/S -1.05% 3.57% 8.69% 53.95% 52.19% 94.92%

For the past year Spero Therapeutics Inc. was less bullish than Zealand Pharma A/S.


Zealand Pharma A/S beats Spero Therapeutics Inc. on 8 of the 12 factors.

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics-based medicines in Denmark. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases. The company markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua. The company's product pipeline includes glepaglutide, a long acting GLP-2 analog for the treatment of short bowel syndrome, which has completed Phase 2 clinical trials; and dasiglucagon, a proprietary glucagon analog for various indications comprising as a dual-hormone artificial pancreas for diabetes treatment, rescue treatment for severe hypoglycemia, and congenital hyperinsulinism. The company has collaboration agreements with Sanofi-Aventis Deutschland GmbH and Boehringer Ingelheim GmbH. The company was founded in 1997 and is headquartered in Copenhagen, Denmark.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.